Publication
MMP1-induced NF-κB activation promotes epithelial-mesenchymal transition and sacituzumab govitecan resistance in hormone receptor-positive breast cancer.
Authors not recorded
Cell Death Dis2025PMID 40287412PMC12033297stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (3)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 3
- drugSacituzumab Govitecancivic_curation1.00
- geneMMP1civic_curation1.00
- variantMMP1 Overexpressioncivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 40287412
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| MMP1 Overexpression1 | ||||||||
| Sacituzumab Govitecan | Estrogen Receptor-positive Breast CancerUNRESOLVED | Predictive | D | Supports Resistance | 3 | accepted | EID12597In the TIMER dataset, levels of MMP1 is increased in cancers compared with normal tissue, where its levels in sacituzumab govitecan (SG)-resistant tumours are higher than SG-sensitive tumours by IHC. … (full text at CIViC) PMID 40287412 · Chen et al., 2025 · Open in CIViC | civic |